HC Wainwright Weighs in on Alumis’ Q2 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Alumis in a research report issued to clients and investors on Friday, May 15th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.55) per share for the quarter, up from their previous forecast of ($0.60). HC Wainwright currently has a “Neutral” rating and a $25.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Alumis’ Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.71) EPS, Q1 2027 earnings at ($0.72) EPS, Q2 2027 earnings at ($0.73) EPS, Q4 2027 earnings at ($0.64) EPS and FY2027 earnings at ($2.84) EPS.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The firm had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%.

Several other equities analysts have also commented on the company. Wells Fargo & Company boosted their price target on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday. Morgan Stanley reissued an “overweight” rating and set a $39.00 price target on shares of Alumis in a research report on Friday. Stifel Nicolaus began coverage on Alumis in a research report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price target on the stock. Loop Capital set a $37.00 price target on Alumis in a research report on Wednesday, January 21st. Finally, Raymond James Financial began coverage on Alumis in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.10.

Alumis Stock Performance

Alumis stock opened at $21.15 on Tuesday. The stock’s 50 day moving average price is $24.31 and its 200 day moving average price is $19.19. The firm has a market capitalization of $2.69 billion, a PE ratio of -10.68 and a beta of -0.31. Alumis has a one year low of $2.76 and a one year high of $30.60.

Institutional Investors Weigh In On Alumis

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC purchased a new stake in Alumis during the 1st quarter worth approximately $46,790,000. Ally Bridge Group NY LLC purchased a new stake in Alumis during the 1st quarter worth approximately $3,678,000. EverSource Wealth Advisors LLC increased its holdings in Alumis by 600.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock worth $69,000 after purchasing an additional 2,684 shares during the last quarter. California State Teachers Retirement System increased its holdings in Alumis by 2,222.5% during the 1st quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock worth $1,781,000 after purchasing an additional 77,364 shares during the last quarter. Finally, Elmind Capital LP bought a new stake in shares of Alumis in the 1st quarter valued at approximately $2,864,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.